Valplus Biotech Profile
Key Indicators
- Authorised Capital ₹ 4.00 Cr
as on 12-12-2024
- Paid Up Capital ₹ 3.00 Cr
as on 12-12-2024
- Company Age 31 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.73 Cr
as on 12-12-2024
- Revenue -55.87%
(FY 2022)
- Profit 74.33%
(FY 2022)
- Ebitda 78.91%
(FY 2022)
- Net Worth -3.83%
(FY 2022)
- Total Assets -2.07%
(FY 2022)
About Valplus Biotech
The Company is engaged in the Agriculture Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 4.00 Cr and a paid-up capital of Rs 3.00 Cr.
The company currently has active open charges totaling ₹2.73 Cr.
Ravi Gupta, Chander Saraogi, Anju Saraogi, and One other member serve as directors at the Company.
- CIN/LLPIN
U01110PN1993PLC129004
- Company No.
129004
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
12 Apr 1993
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Valplus Biotech?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ravi Gupta  | Director | 30-Jun-2005 | Current |
| Chander Saraogi | Director | 20-Oct-2004 | Current |
| Anju Saraogi | Director | 28-Oct-2004 | Current |
| Sanjay Saraogi | Director | 30-Jun-2005 | Current |
Financial Performance of Valplus Biotech.
Valplus Biotech Ltd, for the financial year ended 2022, experienced significant reduction in revenue, with a 55.87% decrease. The company also saw a substantial improvement in profitability, with a 74.33% increase in profit. The company's net worth dipped by a decrease of 3.83%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Valplus Biotech?
In 2022, Valplus Biotech had a promoter holding of 53.29% and a public holding of 46.71%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Frameboxx Animation And Visual Effects Private LimitedActive 6 years 29 daysRavi Gupta is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Ing Vysya Bank Ltd. Creation Date: 24 Mar 2005 | ₹7.30 M | Open |
Union Ban Of India Creation Date: 19 Feb 1996 | ₹2.00 Cr | Open |
How Many Employees Work at Valplus Biotech?
Unlock and access historical data on people associated with Valplus Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Valplus Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Valplus Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
